5 Current news of bioMérieux
rss09-29-2008
bioMérieux has signed a license and development agreement with the German biotechnology company, ProteoSys, for Annexin 3, which will be used to develop a urine-based, confirmatory diagnostic test for prostate cancer. After a research phase, the new test should be developed on the VIDAS® ...
09-15-2008
bioMérieux has acquired the privately held AviaraDx, Inc., a molecular in vitro diagnostics company, based in San Diego, California (USA). AviaraDx’s diagnostic tests, based on their proprietary technologies, are used in the molecular classification of cancers and to assist oncologists in ...
08-16-2007
Sloning BioTechnology GmbH will carry out a feasibility study together with bioMérieux. The aim of the project is to generate a large number of different gene variants of an essential enzyme to be used in diagnostic applications. Sloning will use its Slonomics(TM) industrial scale gene ...
01-09-2007
bioMérieux and ExonHit Therapeutics announced the initiation of their third programme for the screening of cancer from blood. One of the goals is to assist physicians in deciding whether to proceed with surgery for prostate cancer. The collaboration is based on the expertise and intellectual ...
07-28-2005
bioMérieux and DiagnoSwiss announced that DiagnoSwiss has granted bioMérieux with an exclusive worldwide license under the patent rights of DiagnoSwiss relating to the development, manufacturing and marketing of electrochemical microchips in the field of human in vitro diagnostics. The ...
